HARMONY BIOSCIENCES COMPLETES ENROLLMENT OF PHASE 3 REGISTRATIONAL INTUNE STUDY IN IDIOPATHIC HYPERSOMNIA
- Thursday, May 25, 2023, 7:06
- Finance
- Add a comment
PLYMOUTH MEETING, Pa., May 25, 2023 /PRNewswire/ — Harmony Biosciences Holdings, Inc. (“Harmony”) (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that its Phase 3…
About the Author
adminasapcorp has written 41555 stories on this site.